Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Greece

Research and Innovation Action · Running

iPROLEPSIS Iprolepsis: Psoriatic Arthritis Inflammation Explained Through Multi-source Data Analysis Guiding a Novel Personalised Digital Care Ecosystem

Coordinator
Aristotelio Panepistimio Thessalonikis, Greece
Runs
1 January 2023 to 31 December 2027
Status
Running
EU funding
€6.5m
Total cost
€6.5m
Partners
17 organisations in 9 countries
Type
Research and Innovation Action
Grant agreement
101095697

What the project is doing

In the project's own words, from its summary on CORDIS.

Psoriatic Arthritis (PsA) is a chronic, progressive, inflammatory disease affecting 1-2% of the general population, while manifesting in up to 30% of people with psoriasis (PsO). The transition from health to PsA is currently untraceable; diagnosis of early PsA is challenging even in PsO patients. Untimely diagnosis is common and contributes to early deterioration of quality of life, also increasing the burden of the multiple comorbidities associated with PsA.

In this vein, iPROLEPSIS aspires to shed light upon the health-to-PsA transition with a comprehensive multiscale/multifactorial PsA model employing novel trustworthy AI-based analysis of multisource and heterogenous (i.a., in-depth health, environmental, genetic, behavioural) data, digital phenotyping of inflammatory symptoms with emphasis on tracking of motor manifestations using smart devices and wearables, novel optoacoustic imaging-based markers of PsA in the skin and joints, and investigation of the role of mast cells in the PsA transition, to identify key drivers of the disease and support personalized models for PsA risk/progression prediction and monitoring as well as associated inflammation detection and severity assessment.

To ultimately advance PsA diagnosis and care, the models will be translated into a digital health ecosystem comprising dependable tools for supporting healthcare professionals in disease screening, monitoring and treatment via quantitative, explainable evidence, and empowering people with/at risk of PsA with tailored insights and preventive interventions based on actionable factors for educated health management. The project will steer its research and development efforts following a trustworthy framework for ethical, lawful, and robust AI, and a user-centered co-creation approach based on constant involvement of key stakeholders during the design, development, and testing of the digital health ecosystem, securing successful integration of the latter in the continuum of care.

Topics

Who is involved

OrganisationCityCountryRole
Aristotelio Panepistimio ThessalonikisThessalonikiGreeceCoordinator
Ainigma TechnologiesLeuvenBelgiumParticipant
Klinikum Der Technischen Universität München (tum Klinikum)MuenchenGermanyParticipant
Technische Universitaet MuenchenMuenchenGermanyParticipant
Universitatsklinikum ErlangenErlangenGermanyParticipant
Diadikasia Business Consulting Symvouloi Epicheiriseon AeAthinaGreeceParticipant
Ethniko Kentro Erevnas Kai Technologikis AnaptyxisThermi ThessalonikiGreeceParticipant
Wellics Efarmoges Erevnas Kai Pliroforikis Monoprosopi I.k.e.AcharnesGreeceParticipant
The Hebrew University of JerusalemJerusalemIsraelParticipant
Netcompany S.a.LuxembourgLuxembourgParticipant
Smartsol SiaRigaLatviaParticipant
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsParticipant
Stichting Cicero (collectief Initiatief Voor Creatief En Educatief Reuma Onderzoek)RotterdamNetherlandsParticipant
Faculdade De Motricidade HumanaCruz Quebrada LisboaPortugalParticipant
Plux - Wireless Biosignals S.a.LisboaPortugalParticipant
Spr - Sociedade Portuguesa De ReumatologiaLisboaPortugalParticipant
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI